Sonoma Pharmaceuticals, Inc.
SNOANasdaqCIK 1367083HealthcareFiscal year ends Mar 31
Reports and events: 326 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-0620:30 ET | 8-K | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001683168-26-007657 |
| 2026-09-1722:11 ET | 8-K | 5.07 Shareholder vote results | 0001683168-26-007199 |
| 2026-08-1921:27 ET | 8-K | 5.07 Shareholder vote results | 0001683168-26-006608 |
| 2026-08-0612:30 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001683168-26-006024 |
| 2026-07-2820:50 ET | DEF 14A | Proxy statementPeriod 2026-09-16 | 0001683168-26-005810 |
| 2026-06-1820:33 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-26-004975 |
| 2026-06-1620:02 ET | 10-K | Annual reportPeriod 2026-03-31 | 0001683168-26-004871 |
| 2026-05-0520:55 ET | DEF 14A | Proxy statementPeriod 2026-06-24 | 0001683168-26-003495 |
| 2026-04-3021:00 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-26-003381 |
| 2026-04-2300:07 ET | S-1/A | Registration statement, amended | 0001683168-26-003139 |
| 2026-04-1721:23 ET | S-1 | Registration statement | 0001683168-26-003052 |
| 2026-04-0912:30 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001683168-26-002761 |
| 2026-02-1021:01 ET | 10-Q | Quarterly reportPeriod 2025-12-31 | 0001683168-26-000889 |
| 2026-01-2821:01 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001683168-26-000589 |
| 2026-01-1213:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-26-000205 |
| 2026-01-0222:18 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001683168-26-000027 |
| 2025-11-0413:46 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001683168-25-007938 |
| 2025-10-2321:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001683168-25-007750 |
| 2025-10-0920:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001683168-25-007478 |
| 2025-09-2920:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-25-007307 |
| 2025-09-2621:01 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001683168-25-007265 |
| 2025-08-2920:37 ET | 8-K | 5.07 Shareholder vote results | 0001683168-25-006580 |
| 2025-08-0720:02 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001683168-25-005753 |
| 2025-07-1120:15 ET | DEF 14A | Proxy statementPeriod 2025-08-27 | 0001683168-25-005049 |
| 2025-06-1720:01 ET | 10-K | Annual reportPeriod 2025-03-31 | 0001683168-25-004546 |
| 2025-04-2812:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-25-002874 |
| 2025-04-0712:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-25-002294 |
| 2025-03-2520:01 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001683168-25-001857 |
| 2025-02-0521:01 ET | 10-Q | Quarterly reportPeriod 2024-12-31 | 0001683168-25-000736 |
| 2025-01-3021:01 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001683168-25-000611 |
| 2025-01-0322:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001683168-25-000076 |
| 2024-11-2121:01 ET | 8-K | 1.02 Termination of a material agreement | 0001683168-24-008332 |
| 2024-11-0713:36 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001683168-24-007708 |
| 2024-10-2212:30 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-24-007283 |
| 2024-09-2010:02 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-24-006556 |
| 2024-08-2810:03 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-24-006053 |
| 2024-08-2322:08 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-24-005980 |
| 2024-08-2112:30 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001683168-24-005938 |
| 2024-08-0820:01 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001683168-24-005371 |
| 2024-07-0111:30 ET | DEF 14A | Proxy statementPeriod 2024-08-14 | 0001683168-24-004552 |
| 2024-06-2711:31 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-24-004506 |
| 2024-06-1720:13 ET | 10-K | Annual reportPeriod 2024-03-31 | 0001683168-24-004275 |
| 2024-04-0911:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-24-002224 |
| 2024-04-0211:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-24-002051 |
| 2024-03-2220:30 ET | 8-K | 3.01 Delisting notice | 0001683168-24-001635 |
| 2024-03-0821:29 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001683168-24-001399 |
| 2024-02-0821:01 ET | 10-Q | Quarterly reportPeriod 2023-12-31 | 0001683168-24-000781 |
| 2024-01-1012:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-24-000168 |
| 2024-01-0921:47 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001683168-24-000150 |
| 2023-12-2922:23 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001683168-23-009150 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.